Ananya Health lands $100K to push cervical cancer device toward FDA clearance
What's the deal? EHA Impact Ventures (EIV)Dealroom has a profile for this one. Try Dealroom → has invested $100,000 in Ananya HealthDealroom has a profile for this one. Try Dealroom → to advance its cervical cancer prevention device toward US Food and Drug Administration (FDA) clearance. The seed follow-on marks EIV's third investment in the women-led startup.
What is it building? Ananya Health is developing a battery-powered cryoablation device that freezes abnormal cervical cells before they turn cancerous. Unlike traditional cryoablation — which needs specialised doctors, cryogen gas and costly equipment — the device is designed to be portable, affordable and usable by clinicians who already perform pelvic exams, including OB-GYNs and nurse midwives.
Why now? The funding backs Ananya Health's pursuit of FDA 510(k) clearance, the regulatory pathway for marketing the device in the US. It will cover the technical, clinical, and regulatory work needed to reach that milestone by mid-2027, before commercialisation.
What's the endgame? If cleared, the device could expand cervical cancer prevention in underserved communities by allowing procedures at primary healthcare centres rather than specialist facilities. The company has already built a battery-operated cooling system that consistently reaches -40 degrees Celsius, and has partnerships targeting the US, Mexico, Nigeria and India.
"Every clinical milestone we've hit has been built on the assumption that this device needs to work for a midwife in Nairobi and an OB-GYN in Chicago alike," said Anu Parvatiyar, CEO of Ananya Health. "EIV's reinvestment moves us closer to FDA clearance."
The investor's view: EIV CEO Evelyn Castle said medical innovation requires patience, noting the path from concept to commercialisation is rarely linear for devices facing strict regulatory requirements. "Our follow-on investment in Ananya Health reflects our belief that meaningful impact is created when investors remain committed beyond the first cheque," Castle said.
The signal: The reinvestment underscores a founder-centred approach to backing women-led healthcare startups across Africa — betting on long-term capital to carry high-impact medical devices through the slow grind toward regulatory approval and scale.
Image credit: Generated with Gemini
